JP2022130527A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022130527A5 JP2022130527A5 JP2022100650A JP2022100650A JP2022130527A5 JP 2022130527 A5 JP2022130527 A5 JP 2022130527A5 JP 2022100650 A JP2022100650 A JP 2022100650A JP 2022100650 A JP2022100650 A JP 2022100650A JP 2022130527 A5 JP2022130527 A5 JP 2022130527A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- inhibitor
- seq
- thrombin
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 239000003112 inhibitor Substances 0.000 claims 19
- 108090000190 Thrombin Proteins 0.000 claims 8
- 229960004072 thrombin Drugs 0.000 claims 8
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 8
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims 7
- 229940122388 Thrombin inhibitor Drugs 0.000 claims 7
- 108010091748 peptide A Proteins 0.000 claims 7
- 239000003868 thrombin inhibitor Substances 0.000 claims 7
- 235000001014 amino acid Nutrition 0.000 claims 6
- 235000002374 tyrosine Nutrition 0.000 claims 6
- 102000007625 Hirudins Human genes 0.000 claims 4
- 108010007267 Hirudins Proteins 0.000 claims 4
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims 4
- 229940006607 hirudin Drugs 0.000 claims 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000002537 thrombolytic effect Effects 0.000 claims 2
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 102000009123 Fibrin Human genes 0.000 claims 1
- 108010073385 Fibrin Proteins 0.000 claims 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 1
- 108010049003 Fibrinogen Proteins 0.000 claims 1
- 102000008946 Fibrinogen Human genes 0.000 claims 1
- 101800005149 Peptide B Proteins 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229950003499 fibrin Drugs 0.000 claims 1
- 229940012952 fibrinogen Drugs 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108010005636 polypeptide C Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016905231A AU2016905231A0 (en) | 2016-12-16 | Thrombin inhibitors for treatment of stroke and related coagulative disorders | |
| AU2016905231 | 2016-12-16 | ||
| JP2019531876A JP2020501561A (ja) | 2016-12-16 | 2017-12-15 | 脳卒中および関係する凝固性障害の処置のためのトロンビン阻害剤 |
| PCT/AU2017/051405 WO2018107247A1 (en) | 2016-12-16 | 2017-12-15 | Thrombin inhibitors for treatment of stroke and related coagulative disorders |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531876A Division JP2020501561A (ja) | 2016-12-16 | 2017-12-15 | 脳卒中および関係する凝固性障害の処置のためのトロンビン阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022130527A JP2022130527A (ja) | 2022-09-06 |
| JP2022130527A5 true JP2022130527A5 (https=) | 2022-10-11 |
Family
ID=62557849
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531876A Pending JP2020501561A (ja) | 2016-12-16 | 2017-12-15 | 脳卒中および関係する凝固性障害の処置のためのトロンビン阻害剤 |
| JP2022100650A Pending JP2022130527A (ja) | 2016-12-16 | 2022-06-22 | 脳卒中および関係する凝固性障害の処置のためのトロンビン阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531876A Pending JP2020501561A (ja) | 2016-12-16 | 2017-12-15 | 脳卒中および関係する凝固性障害の処置のためのトロンビン阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11091535B2 (https=) |
| EP (1) | EP3555116A4 (https=) |
| JP (2) | JP2020501561A (https=) |
| CN (1) | CN110139871A (https=) |
| AU (1) | AU2017376839B2 (https=) |
| CA (1) | CA3047159A1 (https=) |
| NZ (1) | NZ754781A (https=) |
| WO (1) | WO2018107247A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110590911B (zh) * | 2019-09-30 | 2021-10-22 | 华南理工大学 | 一种含酪氨酸硫酸化修饰的多肽合成方法及其应用 |
| CN114887123B (zh) * | 2022-04-18 | 2023-07-04 | 南通大学 | 水蛭素接枝纳米纤维血管支架材料、制备方法与应用 |
| CN119462906A (zh) * | 2024-11-11 | 2025-02-18 | 武汉元启合生科技有限公司 | 一种酪氨酸硫酸化的重组水蛭素、制备方法及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4323754C1 (de) | 1993-07-15 | 1994-12-01 | Gruenenthal Gmbh | Bifunktionelle Urokinasevarianten mit verbesserten fibrinolytischen Eigenschaften und thrombinhemmender Wirkung |
| US6759384B1 (en) * | 1994-04-26 | 2004-07-06 | Aventis Pharmaceuticals Inc. | Factor Xa inhibitors |
| WO2001000667A2 (en) * | 1999-06-29 | 2001-01-04 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-thrombin peptide from anopheles albimanus salivary gland |
| CA2394803A1 (en) * | 1999-11-24 | 2001-05-31 | Sugen, Inc. | Novel human protein kinases and protein kinase-like enzymes |
| EP1425296B1 (de) * | 2001-09-10 | 2011-04-13 | Novel Science International GmbH | Organische verbindungen mit biologischer wirkung als thrombinhemmer und ihre verwendung |
| JP3648548B2 (ja) * | 2001-10-15 | 2005-05-18 | 国立大学法人三重大学 | 血液凝固阻害活性を有するハマダラカ由来のAs−1蛋白質 |
| DE10301255A1 (de) | 2003-01-15 | 2004-07-29 | Cpi Creative Pharma International Gmbh | Organische Verbindungen mit biologischer Wirkung als Thrombinhemmer und ihre Verwendung |
| JP2008532490A (ja) * | 2005-02-15 | 2008-08-21 | アポロ ライフ サイエンシズ リミテッド | 分子およびそのキメラ分子 |
| WO2007067983A2 (en) * | 2005-12-09 | 2007-06-14 | Wyeth | Sulfotyrosine specific antibodies and uses therefor |
| CN100595208C (zh) * | 2006-07-31 | 2010-03-24 | 浙江中医药大学 | 硫酸化丝素蛋白的制备方法及其在抗凝血药物上的应用 |
| GB0711779D0 (en) * | 2007-06-18 | 2007-07-25 | Univ Singapore | Thrombin inhibitor |
| GB0907698D0 (en) * | 2009-05-05 | 2009-06-10 | Univ Singapore | Method of modifying serine protease inhibitors |
| JP2013540995A (ja) * | 2010-08-18 | 2013-11-07 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス.アー.エール.エル. | 疾患に対する循環バイオマーカー |
| WO2014194015A1 (en) * | 2013-05-30 | 2014-12-04 | Virginia Commonwealth University | Sulfated beta-o4 low molecular weight lignins |
| WO2014194361A1 (en) * | 2013-06-04 | 2014-12-11 | The University Of Sydney | Peptide ligation |
| CN106687482B (zh) * | 2014-09-17 | 2022-01-25 | 诺和诺德股份有限公司 | 能够结合组织因子途径抑制剂(1-161)上的两个表位的抗体 |
| JP2023529993A (ja) * | 2020-06-19 | 2023-07-12 | ザ・ユニバーシティ・オブ・シドニー | 血栓塞栓状態の治療のための改良されたトロンビン阻害剤 |
-
2017
- 2017-12-15 JP JP2019531876A patent/JP2020501561A/ja active Pending
- 2017-12-15 AU AU2017376839A patent/AU2017376839B2/en active Active
- 2017-12-15 US US16/469,804 patent/US11091535B2/en active Active
- 2017-12-15 CA CA3047159A patent/CA3047159A1/en active Pending
- 2017-12-15 CN CN201780078158.2A patent/CN110139871A/zh active Pending
- 2017-12-15 WO PCT/AU2017/051405 patent/WO2018107247A1/en not_active Ceased
- 2017-12-15 NZ NZ754781A patent/NZ754781A/en unknown
- 2017-12-15 EP EP17881550.2A patent/EP3555116A4/en active Pending
-
2022
- 2022-06-22 JP JP2022100650A patent/JP2022130527A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022130527A5 (https=) | ||
| IL261432B1 (en) | Induced binding proteins and methods of use | |
| JP2013502458A5 (https=) | ||
| JP2015512876A5 (https=) | ||
| RU2003104524A (ru) | Masp-2, комплемент-связывающий фермент и его применение | |
| JP2002500886A5 (https=) | ||
| DK1349944T3 (da) | Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens | |
| EP0827539A2 (en) | Kunitz type protease inhibitors | |
| CN116096736A (zh) | 新型冠状病毒rbd融合蛋白 | |
| CN100577686C (zh) | 寡聚肽及其治疗hiv感染的用途 | |
| JP2006516113A5 (https=) | ||
| WO2005123771B1 (en) | Oligomeric peptides and their use for the treatment of hiv infections | |
| JPWO2021191447A5 (https=) | ||
| CZ334095A3 (en) | Compounds containing chains of amino acids, their use and pharmaceutical compositions containing thereof | |
| WO2009038729A3 (en) | Compositions and methods utilizing fibrin beta chain fragments of the bbeta chain of fibrinogen | |
| US20020173620A1 (en) | Bifunctional fusion proteins formed from hirudin and TAP | |
| WO2002002148A3 (en) | Dual recombinant gene therapy compositions and methods of use | |
| US8968728B2 (en) | Chimeric fusion proteins | |
| Sheffield et al. | A long-lasting, plasmin-activatable thrombin inhibitor aids clot lysis in vitro and does not promote bleeding in vivo | |
| JP5053991B2 (ja) | ペプチド安定化化合物とスクリーニング方法 | |
| US7074892B2 (en) | Thrombin generation inhibitors | |
| Li et al. | Total chemical synthesis of human T‐cell leukemia virus type 1 protease via native chemical ligation | |
| Wirsching et al. | Modular design of a novel chimeric protein with combined thrombin inhibitory activity and plasminogen-activating potential | |
| JPWO2022081765A5 (https=) | ||
| Díaz et al. | Cystatins as Calpain Inhibitors: Engineered Chicken Cystatin-and Stefin B-Kininogen Domain 2 Hybrids Support a Cystatin-Like Mode of Interaction with the Catalytic Subunit of µ-Calpain |